CAMBRIDGE, Mass., June 15, 2017 -- Novaseek Research Inc., a health IT for life sciences company, today announced that it has named Bennett Malbon as Chief Technology Officer (CTO) for the company. This is an expansion of Bennett’s current role as Vice President, Technology. As CTO, Bennett will be responsible for driving expansion of Novaseek’s Clinical Data Network for Research (CDNR) platform to meet the evolving needs of biomedical and clinical researchers.
“Novaseek is growing rapidly, and there is a strong need for someone with Bennett’s talent and vision to help drive strategy for the growth and expansion of our CDNR platform,” said Dr. Kate Torchilin, CEO, Novaseek Research. “Bennett has a proven track record of developing comprehensive clinical data solutions for critical needs within the healthcare and life sciences industries. We are excited to have Bennett in this new position.”
“Novaseek is truly innovative in its approach and in the way it enables healthcare organizations and patients to share clinical data and biospecimens for research and provides access for biomedical and clinical researchers to well-categorized patient cohorts for translational and observations studies. I am thrilled to take it to the next level as our team leverages technology to bring better medicines to patients faster,” said Bennett.
Bennett helped found Novaseek Research in 2014, He has more than 20 years of experience in IT and software development. Prior to Novaseek, Bennett was the founding technology architect at Curaspan Health Group, which was acquired by Cardinal Health/NaviHealth in 2016, where he led development and roll-out of a patient transition network electronically connecting 600+ acute care health systems to 8000+ post-acute care providers, payers, and medical transportation services, ultimately handling transitions for approximately 20 percent of acute patients in the U.S. Additionally, Bennett worked with PatientKeeper where he oversaw platform strategy and architecture for physician portal and workflow tools, and with HealthGrid, an ambulatory EMR referral and data exchange network.
Novaseek’s CDNR is an award-winning, cloud-based platform that provides turn-key access to real world data, patients and biospecimens from a network of healthcare organizations. The CDNR platform enables analysis and prospective observation of well-categorized patient cohorts across multiple disease areas. Researchers access CDNR via an intuitive user interface that gives them the ability to define patient cohorts and request biospecimens with detailed clinical data using population analytics and detailed criteria such as demographics, diagnoses, co-morbidities, lab values, medications and treatment histories.
CDNR makes it possible for Novaseek and its hospital partners to serve complex requests, such as, for example, biospecimens and data collected before and after specific cancer treatments, without the need to burden patients with extra blood draws or complex medical questionnaires. This streamlined approach accelerates research, often cutting out up to 12 months of observational study set up and completion and allows more hospitals and patients to participate in biomedical research.
About CDNR
Novaseek’s award-winning novel cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time and enables researchers to define patient cohorts through population analytics, and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies.
About Novaseek
Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please
visit www.novaseekresearch.com.
Media Contact: Terri Clevenger Continuum Health Communications [email protected] (203) 856-4326


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Washington Post Publisher Will Lewis Steps Down After Layoffs
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



